Infliximab as ultima ratio in a case of refractory non-Crohn’s disease complex fistula system: case report and mini-review of the literature - Scorecard - MDSpire

Infliximab as ultima ratio in a case of refractory non-Crohn’s disease complex fistula system: case report and mini-review of the literature

  • By

  • Nada Agbariah

  • Matthias Kis

  • Christine Manser

  • Luc Biedermann

  • Gerhard Rogler

  • June 16, 2026

  • 0 min

Share

Clinical Scorecard: Infliximab as a Last Resort for Managing Refractory Non-Crohn’s Disease Fistula Complex: A Case Study and Brief Literature Review

At a Glance

CategoryDetail
ConditionRefractory Non-Crohn's Disease Fistula Complex
Key Mechanisms
Target Population
Care Setting

Key Highlights

  • highlight_5

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Regular follow-up to assess clinical improvement, including specific parameters such as wound healing and infection signs.

      Risks

        Patient & Prescribing Data

        Include previous treatment outcomes for context.

        Clinical Best Practices

        • best_practice_2

        Related Resources & Content

        Original Source(s)

        Infliximab as ultima ratio in a case of refractory non-Crohn’s disease complex fistula system: case report and mini-review of the literature

        • by Nada Agbariah, Matthias Kis, Christine Manser, Luc Biedermann, Gerhard Rogler

        • June 16, 2026

        Related Content

        Development and validation of a machine learning model to evaluate survival in patients with newly diagnosed breast cancer with liver metastasis

        Commentary: Safety and efficacy of a novel fecal microbiota transplantation method using hydrogen nanobubble water without antibiotics or bowel cleansing in children with autism spectrum disorder

        Hypoxia induced DNMT3B and SHP2 signaling promoted HCC via suppressing P53 and MYH11 protein expression